Aducanumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Aducanumab" in English language version.

refsWebsite

Global rank English rank

75web.archive.org

1^st place

12nih.gov

4^th place

9doi.org

2^nd place

6semanticscholar.org

11^th place

8^th place

6nytimes.com

7^th place

6washingtonpost.com

34^th place

27^th place

5fda.gov

447^th place

338^th place

4statnews.com

8,771^st place

5,253^rd place

3cnn.com

28^th place

26^th place

3medscape.com

719^th place

636^th place

3biogen.com

low place

3bbc.com

20^th place

30^th place

3bloomberg.com

99^th place

77^th place

2fiercepharma.com

low place

8,921^st place

2npr.org

92^nd place

72^nd place

2worldcat.org

5^th place

2go.com

48^th place

39^th place

2cms.gov

low place

2europa.eu

68^th place

117^th place

2kff.org

low place

8,628^th place

1harvard.edu

18^th place

17^th place

1apnews.com

129^th place

89^th place

1xconomy.com

low place

6,978^th place

1uzh.ch

3,633^rd place

3,091^st place

1time.com

61^st place

54^th place

1cnbc.com

220^th place

155^th place

1bloomberglaw.com

5,670^th place

3,086^th place

1bbc.co.uk

8^th place

10^th place

1scientificamerican.com

896^th place

674^th place

1biospace.com

low place

7,595^th place

1biopharmadive.com

low place

1biopharma-reporter.com

low place

1citizen.org

low place

1icer.org

low place

1house.gov

529^th place

314^th place

1forbes.com

54^th place

48^th place

1endpts.com

low place

1alz.org

low place

1alzheimer.ca

low place

1alzfdn.org

low place

1thehill.com

476^th place

282^nd place

1seekingalpha.com

5,344^th place

3,420^th place

1economist.com

254^th place

236^th place

1bcbsm.com

low place

1medicare.gov

low place

1politico.com

312^th place

197^th place

1newchoicehealth.com

low place

1reuters.com

49^th place

47^th place

1handle.net

102^nd place

76^th place

alz.org

"It's a New Day in the Fight Against Alzheimer's — Aducanumab Approved". Alzheimer's Association. Archived from the original on 10 June 2021. Retrieved 11 June 2021.

alzfdn.org

"Alzheimer's Foundation of America Statement on FDA Approving First New Alzheimer's Medication in Nearly 20 Years". Alzheimer's Foundation of America. 7 June 2021. Archived from the original on 11 June 2021. Retrieved 11 June 2021.

alzheimer.ca

"First new treatment for Alzheimer's disease approved in nearly two decades offers hope for people living with dementia". Alzheimer Society of Canada. 7 June 2021. Archived from the original on 10 June 2021. Retrieved 11 June 2021.

apnews.com

Marchione M, Perrone M (6 November 2020). "FDA panel urges rejection of experimental Alzheimer's drug". Associated Press. Archived from the original on 17 November 2021. Retrieved 8 June 2021.

bbc.co.uk

Roberts M (22 October 2019). "First drug to slow Alzheimer's may be available soon". BBC News. Archived from the original on 5 December 2019. Retrieved 22 October 2019.

bbc.com

Foster L (26 October 2019). "Drug 'could be biggest Alzheimer's development'". BBC News. Archived from the original on 19 December 2019. Retrieved 26 October 2019.
"Alzheimer's drug aducanumab not approved for use in EU". BBC News Online. 17 December 2021. Archived from the original on 21 December 2021. Retrieved 21 December 2021.
"US approves first new Alzheimer's drug in 20 years". BBC News Online. 7 June 2021. Archived from the original on 30 September 2021. Retrieved 7 June 2021.

bcbsm.com

"How do drug tiers work?". Blue Cross Blue Shield of Michigan. Archived from the original on 15 June 2021. Retrieved 14 June 2021.

biogen.com

investors.biogen.com

"Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease". Biogen. 21 March 2019. Archived from the original on 13 October 2023.
"Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies". Biogen. 22 October 2019. Archived from the original on 29 May 2020. Retrieved 22 October 2019.
"Biogen to Realign Resources for Alzheimer's Disease Franchise" (Press release). 31 January 2024. Archived from the original on 31 January 2024. Retrieved 31 January 2024.

biopharma-reporter.com

"Aducanumab rejected in the EU: Biogen to ask EMA to re-examine application". biopharma reporter. 20 December 2021. Archived from the original on 20 December 2021. Retrieved 21 December 2021.

biopharmadive.com

Bell J (6 February 2023). "Eisai gives first glimpse into Alzheimer's drug launch". BiopharmaDive. Washington, D.C.: Informa. Archived from the original on 6 February 2023. Retrieved 11 February 2023.

biospace.com

"FDA Accepts BLA for Biogen's Alzheimer's Drug, Grants Priority Review". BioSpace. 7 August 2020. Archived from the original on 2 September 2021. Retrieved 1 September 2021.

bloomberg.com

Langreth R (10 June 2021). "Harvard Expert Quits FDA Panel as Furor Over Biogen Drug Grows". Bloomberg. Archived from the original on 10 June 2021. Retrieved 10 June 2021.
"Harvard Expert Quits FDA Panel as Biogen Drug Furor Grows". Bloomberg. 10 June 2021. Archived from the original on 10 June 2021. Retrieved 1 September 2021.
Edney A (17 June 2021). "Key Democrat Manchin Bashes FDA Leader on Alzheimer's Approval". Bloomberg News. Archived from the original on 2 July 2021. Retrieved 20 June 2021.

bloomberglaw.com

news.bloomberglaw.com

Annett T. "Biogen Plunges More Than 25 Percent on Alzheimer's Setback". Bloomberg News. Archived from the original on 8 June 2021. Retrieved 6 December 2019.

citizen.org

"Statement: FDA's Decision to Approve Aducanumab for Alzheimer's Disease Shows Reckless Disregard for Science, Severely Damages Agency's Credibility". Public Citizen. 7 June 2021. Archived from the original on 11 June 2021. Retrieved 11 June 2021.

cms.gov

"NCA - Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (CAG-00460N) - Decision Memo". Center for Medicare and Medicaid Services. Archived from the original on 5 June 2022. Retrieved 9 June 2022.
"National Coverage Analysis (NCA) Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N)". Centers for Medicare & Medicaid Services (CMS). 27 September 2013. Archived from the original on 28 June 2021. Retrieved 28 June 2021.

cnbc.com

Li Y (21 March 2019). "Biogen posts its the worst day in 14 years after ending trial for blockbuster Alzheimer's drug". CNBC. Archived from the original on 7 June 2021. Retrieved 21 March 2019.

cnn.com

Gumbrecht J (9 July 2021). "Acting FDA commissioner calls for independent investigation into approval of Alzheimer's drug". CNN. Archived from the original on 13 August 2021. Retrieved 1 September 2021.
Howard J, Gumbrecht J (23 October 2019). "Drugmaker to seek approval for Alzheimer's treatment". CNN. Archived from the original on 24 August 2021. Retrieved 23 October 2019.
Jen Christensen (29 December 2022). "House investigation says FDA approval process of Alzheimer's drug was 'rife with irregularities'". CNN. Archived from the original on 31 January 2024. Retrieved 31 January 2024.

doi.org

Walsh S, Merrick R, Milne R, Brayne C (July 2021). "Aducanumab for Alzheimer's disease?". BMJ. 374: n1682. doi:10.1136/bmj.n1682. PMC 8258645. PMID 34226181.
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. (September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–56. Bibcode:2016Natur.537...50S. doi:10.1038/nature19323. PMID 27582220. S2CID 205250312.
Abyadeh M, Gupta V, Gupta V, Chitranshi N, Wu Y, Amirkhani A, et al. (2021). "Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease". Aging and Disease. 12 (8): 1964–1976. doi:10.14336/AD. PMC 8612603. PMID 34881080.
Toyn J (May 2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Review of Clinical Pharmacology. 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157. S2CID 35158630.
Mahase E (June 2021). "Three FDA advisory panel members resign over approval of Alzheimer's drug". BMJ. 373: n1503. doi:10.1136/bmj.n1503. PMID 34117086. S2CID 235405355.
Hansen SB, Wang H (September 2023). "The shared role of cholesterol in neuronal and peripheral inflammation". Pharmacology & Therapeutics. 249: 108486. doi:10.1016/j.pharmthera.2023.108486. PMID 37390970. S2CID 259303593.
Hansen SB (18 July 2023). "Cholesterol's Function and Origin in the Alzheimer's Disease Brain". Journal of Alzheimer's Disease. 94 (2): 471–472. doi:10.3233/JAD-230538. PMID 37393509. S2CID 259307724.
Sevigny J, Chiao P, Williams L, Chen T, Ling Y, O'Gorman J, et al. (July 2015). "O4-04-05: Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study". Alzheimer's & Dementia. 11 (7S_Part_6): 277. doi:10.1016/j.jalz.2015.07.367. S2CID 54339030.
Manyara AM, Ciani O, Taylor RS (January 2022). "A call for better reporting of trials using surrogate primary endpoints". Alzheimer's & Dementia. 8 (1): e12340. doi:10.1002/trc2.12340. PMC 9323346. PMID 35910671.

economist.com

"Aduhelm may not cure Alzheimer's, but it might help fix drug prices". The Economist. 15 July 2021. ISSN 0013-0613. Archived from the original on 1 September 2021. Retrieved 20 July 2021.

endpts.com

Jason M (4 August 2021). "HHS extends Aduhelm investigation into the accelerated approval pathway, wading into a brewing controversy". Endpoints News. Archived from the original on 2 September 2021. Retrieved 1 September 2021.

europa.eu

ema.europa.eu

"Refusal of the marketing authorisation for Aduhelm (aducanumab) EMA/112932/2022 Rev.1 / EMEA/H/C/005558" (PDF). European Medicines Agency (EMA). February 2022. Archived from the original on 17 December 2021.
"Aduhelm: Withdrawn application". European Medicines Agency (EMA). 9 March 2023. Archived from the original on 10 July 2023. Retrieved 9 July 2023.

fda.gov

"FDA Grants Accelerated Approval for Alzheimer's Drug". U.S. Food and Drug Administration (FDA) (Press release). 7 June 2021. Archived from the original on 8 June 2021. Retrieved 7 June 2021. This article incorporates text from this source, which is in the public domain.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
"FDA's Decision to Approve New Treatment for Alzheimer's Disease". U.S. Food and Drug Administration (FDA). 7 June 2021. Archived from the original on 8 June 2021. Retrieved 7 June 2021.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

accessdata.fda.gov

"Drug Approval Package: Aduhelm (aducanumab-avwa)". U.S. Food and Drug Administration (FDA). 22 June 2021. Archived from the original on 2 September 2021. Retrieved 1 September 2021.

fiercepharma.com

Liu A (15 March 2022). "Biogen takes full control of troubled Aduhelm in revamped Eisai deal". Fierce Pharma. Archived from the original on 21 March 2022. Retrieved 21 March 2022.
Higgins-Dunn N (22 September 2021). "Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm". Fierce Pharma. Archived from the original on 11 December 2021. Retrieved 11 December 2021.

forbes.com

Rosenbaum L (9 July 2021). "FDA Commissioner Calls For Inspector General Probe Into Biogen Alzheimer's Drug Approval". Forbes. Archived from the original on 19 November 2021. Retrieved 1 September 2021.

go.com

abcnews.go.com

"Biogen will stop selling its controversial Alzheimer's drug Aduhelm". ABC News. Archived from the original on 31 January 2024. Retrieved 1 February 2024.
Murphy T (31 January 2024). "Biogen will stop selling its controversial Alzheimer's drug Aduhelm". Associated Press. Archived from the original on 31 January 2024. Retrieved 31 January 2024.

handle.net

hdl.handle.net

World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.

harvard.edu

ui.adsabs.harvard.edu

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. (September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–56. Bibcode:2016Natur.537...50S. doi:10.1038/nature19323. PMID 27582220. S2CID 205250312.

house.gov

energycommerce.house.gov

"The High Price of Aduhelm's Approval: An Investigation into FDA's Atypical Review Process and Biogen's Aggressive Launch Plans" (PDF). Committee on Energy and Commerce/Committee on Oversight and Accountability. December 2022. Archived (PDF) from the original on 31 December 2022. Retrieved 31 December 2022.

icer.org

"ICER Issues Statement on the FDA's Approval of Aducanumab for Alzheimer's Disease". ICER. Archived from the original on 11 June 2021. Retrieved 11 June 2021.

kff.org

"FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries". Kaiser Family Foundation (KFF). 10 June 2021. Archived from the original on 1 September 2021. Retrieved 1 September 2021.
"Medicare's Coverage Decision for the New Alzheimer's Drug and Why It Matters". KFF. 14 January 2022. Archived from the original on 20 July 2022. Retrieved 20 July 2022.

medicare.gov

"What Medicare Part D drug plans cover". US Centers for Medicare & Medicaid Services. Archived from the original on 19 November 2021. Retrieved 14 June 2021.

medscape.com

McNamara D (28 May 2020). "Mixed Results for Aducanumab in Two Phase 3 AD Trials". Medscape. Archived from the original on 8 June 2021. Retrieved 11 August 2020.
Ault A (5 May 2021). "FDA Reviewers: Why We Are Against Approval of Aducanumab for Alzheimer's". Medscape Medical News. Archived from the original on 10 June 2021. Retrieved 9 June 2021.
"Alzheimer's Association Denies Conflict in Aducanumab Support". Medscape. Archived from the original on 8 August 2022. Retrieved 8 August 2022.

newchoicehealth.com

Poslusny C (31 July 2018). "How much should your PET scan cost?". New Choice Health Blog. Archived from the original on 24 June 2021. Retrieved 19 June 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Walsh S, Merrick R, Milne R, Brayne C (July 2021). "Aducanumab for Alzheimer's disease?". BMJ. 374: n1682. doi:10.1136/bmj.n1682. PMC 8258645. PMID 34226181.
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. (September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–56. Bibcode:2016Natur.537...50S. doi:10.1038/nature19323. PMID 27582220. S2CID 205250312.
Abyadeh M, Gupta V, Gupta V, Chitranshi N, Wu Y, Amirkhani A, et al. (2021). "Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease". Aging and Disease. 12 (8): 1964–1976. doi:10.14336/AD. PMC 8612603. PMID 34881080.
Toyn J (May 2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Review of Clinical Pharmacology. 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157. S2CID 35158630.
Mahase E (June 2021). "Three FDA advisory panel members resign over approval of Alzheimer's drug". BMJ. 373: n1503. doi:10.1136/bmj.n1503. PMID 34117086. S2CID 235405355.
Hansen SB, Wang H (September 2023). "The shared role of cholesterol in neuronal and peripheral inflammation". Pharmacology & Therapeutics. 249: 108486. doi:10.1016/j.pharmthera.2023.108486. PMID 37390970. S2CID 259303593.
Hansen SB (18 July 2023). "Cholesterol's Function and Origin in the Alzheimer's Disease Brain". Journal of Alzheimer's Disease. 94 (2): 471–472. doi:10.3233/JAD-230538. PMID 37393509. S2CID 259307724.
Manyara AM, Ciani O, Taylor RS (January 2022). "A call for better reporting of trials using surrogate primary endpoints". Alzheimer's & Dementia. 8 (1): e12340. doi:10.1002/trc2.12340. PMC 9323346. PMID 35910671.

ncbi.nlm.nih.gov

Walsh S, Merrick R, Milne R, Brayne C (July 2021). "Aducanumab for Alzheimer's disease?". BMJ. 374: n1682. doi:10.1136/bmj.n1682. PMC 8258645. PMID 34226181.
Abyadeh M, Gupta V, Gupta V, Chitranshi N, Wu Y, Amirkhani A, et al. (2021). "Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease". Aging and Disease. 12 (8): 1964–1976. doi:10.14336/AD. PMC 8612603. PMID 34881080.
Manyara AM, Ciani O, Taylor RS (January 2022). "A call for better reporting of trials using surrogate primary endpoints". Alzheimer's & Dementia. 8 (1): e12340. doi:10.1002/trc2.12340. PMC 9323346. PMID 35910671.

dailymed.nlm.nih.gov

"Aduhelm- aducanumab injection, solution". DailyMed. Archived from the original on 14 June 2021. Retrieved 14 June 2021.

npr.org

"3 Experts Have Resigned From An FDA Committee Over Alzheimer's Drug Approval". NPR. 11 June 2021. Archived from the original on 11 June 2021. Retrieved 11 June 2021.
"Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually". NPR. Associated Press. 10 June 2021. Archived from the original on 10 June 2021. Retrieved 11 June 2021.

nytimes.com

Belluck P, Robbins R (10 June 2021). "Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug". The New York Times. Archived from the original on 14 November 2021. Retrieved 14 June 2021.
Belluck P (22 November 2021). "Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug". The New York Times. ISSN 0362-4331. Archived from the original on 20 July 2022. Retrieved 20 July 2022.
Belluck P, Robbins R (5 June 2021). "Alzheimer's Drug Poses a Dilemma for the F.D.A." The New York Times. Archived from the original on 19 November 2021. Retrieved 7 June 2021.
"Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials". The New York Times. 7 April 2022. Archived from the original on 23 March 2023. Retrieved 9 July 2023.
Belluck P, Robbins R (7 June 2021). "F.D.A. Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works". The New York Times. Archived from the original on 14 November 2021. Retrieved 7 June 2021.
Belluck P, Kaplan S, Robbins R (20 July 2021). "How Aduhelm, an Unproven Alzheimer's Drug, Got Approved". New York Times. Archived from the original on 4 August 2021. Retrieved 5 August 2021.

politico.com

Foley KE, Lim D, Roubein R (15 June 2021). "New Alzheimer's drug could be 'devastating' for Medicare". Politico. Archived from the original on 27 June 2021. Retrieved 19 June 2021.

reuters.com

Khandekar A (20 December 2021). "Biogen halves price of Alzheimer's drug to $28,200". Reuters. Archived from the original on 20 December 2021. Retrieved 20 July 2022.

scientificamerican.com

Herper M (22 October 2019). "In shocking reversal, Biogen to submit Alzheimer's drug for approval". Scientific American. Archived from the original on 5 April 2023. Retrieved 15 November 2023. In one study, called Emerge, patients on the high-dose aducanumab had a 23% reduction in their rate of decline compared to those on placebo; those who were on the low dose were 11% lower than placebo, but that result was not statistically significant. But in the second trial, Engage, the decrease was only 2% in patients on the high dose.

seekingalpha.com

"Biogen CEO: committed to gathering new data on FDA-approved Alzheimer's drug". 7 June 2021. Archived from the original on 7 June 2021. Retrieved 7 June 2021.

semanticscholar.org

api.semanticscholar.org

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. (September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–56. Bibcode:2016Natur.537...50S. doi:10.1038/nature19323. PMID 27582220. S2CID 205250312.
Toyn J (May 2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Review of Clinical Pharmacology. 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157. S2CID 35158630.
Mahase E (June 2021). "Three FDA advisory panel members resign over approval of Alzheimer's drug". BMJ. 373: n1503. doi:10.1136/bmj.n1503. PMID 34117086. S2CID 235405355.
Hansen SB, Wang H (September 2023). "The shared role of cholesterol in neuronal and peripheral inflammation". Pharmacology & Therapeutics. 249: 108486. doi:10.1016/j.pharmthera.2023.108486. PMID 37390970. S2CID 259303593.
Hansen SB (18 July 2023). "Cholesterol's Function and Origin in the Alzheimer's Disease Brain". Journal of Alzheimer's Disease. 94 (2): 471–472. doi:10.3233/JAD-230538. PMID 37393509. S2CID 259307724.
Sevigny J, Chiao P, Williams L, Chen T, Ling Y, O'Gorman J, et al. (July 2015). "O4-04-05: Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study". Alzheimer's & Dementia. 11 (7S_Part_6): 277. doi:10.1016/j.jalz.2015.07.367. S2CID 54339030.

statnews.com

Karlawish J (30 May 2021). "If the FDA approves Biogen's Alzheimer's treatment, I won't prescribe it". STAT. Archived from the original on 7 June 2021. Retrieved 7 June 2021.
"Third member of FDA expert committee resigns over Alzheimer's decision". STAT. 10 June 2021. Archived from the original on 2 September 2021. Retrieved 1 September 2021.
Feuerstein A, Herper M, Garde D (29 June 2021). "How Biogen used an FDA back channel to win Alzheimer's drug approval". STAT. Archived from the original on 2 September 2021. Retrieved 1 September 2021.
Feuerstein A, Garde D (22 September 2021). "Biogen's Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures". Stat. Archived from the original on 17 December 2021. Retrieved 11 December 2021.

thehill.com

Weixel N (29 December 2022). "House investigation faults FDA approval of Alzheimer's drug Aduhelm as 'rife with irregularities'". The Hill. Archived from the original on 4 January 2023. Retrieved 4 January 2023.

time.com

Ducharme J (21 March 2019). "Biogen Halts Promising Alzheimer's Drug Trials Due to Disappointing Results". Time. Archived from the original on 2 June 2019. Retrieved 21 March 2019.

uzh.ch

media.uzh.ch

"Approval for New Alzheimer's Drug Developed at UZH". University of Zurich. 7 June 2021. Archived from the original on 17 November 2021. Retrieved 16 November 2021.

washingtonpost.com

McGinley L (22 June 2021). "FDA releases fresh details on internal debate over controversial Alzheimer's drug". The Washington Post. Archived from the original on 19 November 2021. Retrieved 24 June 2021.
Kunkle F (6 December 2019). "Biogen's potential new drug for Alzheimer's disease gets cautiously optimistic review following presentation". The Washington Post. Archived from the original on 2 January 2020. Retrieved 6 December 2019.
McGinley L (17 June 2021). "Furor rages over FDA approval of controversial Alzheimer's drug". The Washington Post. Archived from the original on 19 November 2021. Retrieved 19 June 2021.
McGinley L (9 June 2021). "Two members of an FDA advisory committee quit after approval of controversial Alzheimer's drug". The Washington Post. Archived from the original on 10 June 2021. Retrieved 9 June 2021.
Johnson M (29 December 2022). "House investigation faults FDA, Biogen for Alzheimer's drug approval". The Washington Post. Archived from the original on 30 December 2022. Retrieved 31 December 2022.
Cunningham PW (16 June 2021). "The Health 202: The pricey new Alzheimer's drug adds to the pressure for drug price controls". Archived from the original on 19 November 2021. Retrieved 1 September 2021.

web.archive.org

"Aduhelm- aducanumab injection, solution". DailyMed. Archived from the original on 14 June 2021. Retrieved 14 June 2021.
"FDA Grants Accelerated Approval for Alzheimer's Drug". U.S. Food and Drug Administration (FDA) (Press release). 7 June 2021. Archived from the original on 8 June 2021. Retrieved 7 June 2021. This article incorporates text from this source, which is in the public domain.
Liu A (15 March 2022). "Biogen takes full control of troubled Aduhelm in revamped Eisai deal". Fierce Pharma. Archived from the original on 21 March 2022. Retrieved 21 March 2022.
"Drug Approval Package: Aduhelm (aducanumab-avwa)". U.S. Food and Drug Administration (FDA). 22 June 2021. Archived from the original on 2 September 2021. Retrieved 1 September 2021.
"3 Experts Have Resigned From An FDA Committee Over Alzheimer's Drug Approval". NPR. 11 June 2021. Archived from the original on 11 June 2021. Retrieved 11 June 2021.
Belluck P, Robbins R (10 June 2021). "Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug". The New York Times. Archived from the original on 14 November 2021. Retrieved 14 June 2021.
McGinley L (22 June 2021). "FDA releases fresh details on internal debate over controversial Alzheimer's drug". The Washington Post. Archived from the original on 19 November 2021. Retrieved 24 June 2021.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
Marchione M, Perrone M (6 November 2020). "FDA panel urges rejection of experimental Alzheimer's drug". Associated Press. Archived from the original on 17 November 2021. Retrieved 8 June 2021.
Belluck P (22 November 2021). "Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug". The New York Times. ISSN 0362-4331. Archived from the original on 20 July 2022. Retrieved 20 July 2022.
"FDA's Decision to Approve New Treatment for Alzheimer's Disease". U.S. Food and Drug Administration (FDA). 7 June 2021. Archived from the original on 8 June 2021. Retrieved 7 June 2021.
Gumbrecht J (9 July 2021). "Acting FDA commissioner calls for independent investigation into approval of Alzheimer's drug". CNN. Archived from the original on 13 August 2021. Retrieved 1 September 2021.
"Biogen will stop selling its controversial Alzheimer's drug Aduhelm". ABC News. Archived from the original on 31 January 2024. Retrieved 1 February 2024.
Zacks R (20 November 2007). "Biogen Inks $380 Million Deal with Swiss Company". Xconomy. Archived from the original on 30 October 2019. Retrieved 18 August 2015.
"Approval for New Alzheimer's Drug Developed at UZH". University of Zurich. 7 June 2021. Archived from the original on 17 November 2021. Retrieved 16 November 2021.
Karlawish J (30 May 2021). "If the FDA approves Biogen's Alzheimer's treatment, I won't prescribe it". STAT. Archived from the original on 7 June 2021. Retrieved 7 June 2021.
Belluck P, Robbins R (5 June 2021). "Alzheimer's Drug Poses a Dilemma for the F.D.A." The New York Times. Archived from the original on 19 November 2021. Retrieved 7 June 2021.
Ducharme J (21 March 2019). "Biogen Halts Promising Alzheimer's Drug Trials Due to Disappointing Results". Time. Archived from the original on 2 June 2019. Retrieved 21 March 2019.
Li Y (21 March 2019). "Biogen posts its the worst day in 14 years after ending trial for blockbuster Alzheimer's drug". CNBC. Archived from the original on 7 June 2021. Retrieved 21 March 2019.
Annett T. "Biogen Plunges More Than 25 Percent on Alzheimer's Setback". Bloomberg News. Archived from the original on 8 June 2021. Retrieved 6 December 2019.
McNamara D (28 May 2020). "Mixed Results for Aducanumab in Two Phase 3 AD Trials". Medscape. Archived from the original on 8 June 2021. Retrieved 11 August 2020.
"Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease". Biogen. 21 March 2019. Archived from the original on 13 October 2023.
Roberts M (22 October 2019). "First drug to slow Alzheimer's may be available soon". BBC News. Archived from the original on 5 December 2019. Retrieved 22 October 2019.
Foster L (26 October 2019). "Drug 'could be biggest Alzheimer's development'". BBC News. Archived from the original on 19 December 2019. Retrieved 26 October 2019.
Kunkle F (6 December 2019). "Biogen's potential new drug for Alzheimer's disease gets cautiously optimistic review following presentation". The Washington Post. Archived from the original on 2 January 2020. Retrieved 6 December 2019.
Howard J, Gumbrecht J (23 October 2019). "Drugmaker to seek approval for Alzheimer's treatment". CNN. Archived from the original on 24 August 2021. Retrieved 23 October 2019.
Herper M (22 October 2019). "In shocking reversal, Biogen to submit Alzheimer's drug for approval". Scientific American. Archived from the original on 5 April 2023. Retrieved 15 November 2023. In one study, called Emerge, patients on the high-dose aducanumab had a 23% reduction in their rate of decline compared to those on placebo; those who were on the low dose were 11% lower than placebo, but that result was not statistically significant. But in the second trial, Engage, the decrease was only 2% in patients on the high dose.
"Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies". Biogen. 22 October 2019. Archived from the original on 29 May 2020. Retrieved 22 October 2019.
"FDA Accepts BLA for Biogen's Alzheimer's Drug, Grants Priority Review". BioSpace. 7 August 2020. Archived from the original on 2 September 2021. Retrieved 1 September 2021.
Bell J (6 February 2023). "Eisai gives first glimpse into Alzheimer's drug launch". BiopharmaDive. Washington, D.C.: Informa. Archived from the original on 6 February 2023. Retrieved 11 February 2023.
"NCA - Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (CAG-00460N) - Decision Memo". Center for Medicare and Medicaid Services. Archived from the original on 5 June 2022. Retrieved 9 June 2022.
"Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials". The New York Times. 7 April 2022. Archived from the original on 23 March 2023. Retrieved 9 July 2023.
"Refusal of the marketing authorisation for Aduhelm (aducanumab) EMA/112932/2022 Rev.1 / EMEA/H/C/005558" (PDF). European Medicines Agency (EMA). February 2022. Archived from the original on 17 December 2021.
"Aducanumab rejected in the EU: Biogen to ask EMA to re-examine application". biopharma reporter. 20 December 2021. Archived from the original on 20 December 2021. Retrieved 21 December 2021.
"Alzheimer's drug aducanumab not approved for use in EU". BBC News Online. 17 December 2021. Archived from the original on 21 December 2021. Retrieved 21 December 2021.
"Aduhelm: Withdrawn application". European Medicines Agency (EMA). 9 March 2023. Archived from the original on 10 July 2023. Retrieved 9 July 2023.
"Biogen to Realign Resources for Alzheimer's Disease Franchise" (Press release). 31 January 2024. Archived from the original on 31 January 2024. Retrieved 31 January 2024.
Murphy T (31 January 2024). "Biogen will stop selling its controversial Alzheimer's drug Aduhelm". Associated Press. Archived from the original on 31 January 2024. Retrieved 31 January 2024.
Ault A (5 May 2021). "FDA Reviewers: Why We Are Against Approval of Aducanumab for Alzheimer's". Medscape Medical News. Archived from the original on 10 June 2021. Retrieved 9 June 2021.
"US approves first new Alzheimer's drug in 20 years". BBC News Online. 7 June 2021. Archived from the original on 30 September 2021. Retrieved 7 June 2021.
Belluck P, Robbins R (7 June 2021). "F.D.A. Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works". The New York Times. Archived from the original on 14 November 2021. Retrieved 7 June 2021.
McGinley L (17 June 2021). "Furor rages over FDA approval of controversial Alzheimer's drug". The Washington Post. Archived from the original on 19 November 2021. Retrieved 19 June 2021.
"Third member of FDA expert committee resigns over Alzheimer's decision". STAT. 10 June 2021. Archived from the original on 2 September 2021. Retrieved 1 September 2021.
McGinley L (9 June 2021). "Two members of an FDA advisory committee quit after approval of controversial Alzheimer's drug". The Washington Post. Archived from the original on 10 June 2021. Retrieved 9 June 2021.
Langreth R (10 June 2021). "Harvard Expert Quits FDA Panel as Furor Over Biogen Drug Grows". Bloomberg. Archived from the original on 10 June 2021. Retrieved 10 June 2021.
"Harvard Expert Quits FDA Panel as Biogen Drug Furor Grows". Bloomberg. 10 June 2021. Archived from the original on 10 June 2021. Retrieved 1 September 2021.
"Statement: FDA's Decision to Approve Aducanumab for Alzheimer's Disease Shows Reckless Disregard for Science, Severely Damages Agency's Credibility". Public Citizen. 7 June 2021. Archived from the original on 11 June 2021. Retrieved 11 June 2021.
"ICER Issues Statement on the FDA's Approval of Aducanumab for Alzheimer's Disease". ICER. Archived from the original on 11 June 2021. Retrieved 11 June 2021.
Edney A (17 June 2021). "Key Democrat Manchin Bashes FDA Leader on Alzheimer's Approval". Bloomberg News. Archived from the original on 2 July 2021. Retrieved 20 June 2021.
Belluck P, Kaplan S, Robbins R (20 July 2021). "How Aduhelm, an Unproven Alzheimer's Drug, Got Approved". New York Times. Archived from the original on 4 August 2021. Retrieved 5 August 2021.
"The High Price of Aduhelm's Approval: An Investigation into FDA's Atypical Review Process and Biogen's Aggressive Launch Plans" (PDF). Committee on Energy and Commerce/Committee on Oversight and Accountability. December 2022. Archived (PDF) from the original on 31 December 2022. Retrieved 31 December 2022.
Johnson M (29 December 2022). "House investigation faults FDA, Biogen for Alzheimer's drug approval". The Washington Post. Archived from the original on 30 December 2022. Retrieved 31 December 2022.
Rosenbaum L (9 July 2021). "FDA Commissioner Calls For Inspector General Probe Into Biogen Alzheimer's Drug Approval". Forbes. Archived from the original on 19 November 2021. Retrieved 1 September 2021.
Feuerstein A, Herper M, Garde D (29 June 2021). "How Biogen used an FDA back channel to win Alzheimer's drug approval". STAT. Archived from the original on 2 September 2021. Retrieved 1 September 2021.
Jason M (4 August 2021). "HHS extends Aduhelm investigation into the accelerated approval pathway, wading into a brewing controversy". Endpoints News. Archived from the original on 2 September 2021. Retrieved 1 September 2021.
"It's a New Day in the Fight Against Alzheimer's — Aducanumab Approved". Alzheimer's Association. Archived from the original on 10 June 2021. Retrieved 11 June 2021.
"First new treatment for Alzheimer's disease approved in nearly two decades offers hope for people living with dementia". Alzheimer Society of Canada. 7 June 2021. Archived from the original on 10 June 2021. Retrieved 11 June 2021.
"Alzheimer's Foundation of America Statement on FDA Approving First New Alzheimer's Medication in Nearly 20 Years". Alzheimer's Foundation of America. 7 June 2021. Archived from the original on 11 June 2021. Retrieved 11 June 2021.
"Alzheimer's Association Denies Conflict in Aducanumab Support". Medscape. Archived from the original on 8 August 2022. Retrieved 8 August 2022.
Weixel N (29 December 2022). "House investigation faults FDA approval of Alzheimer's drug Aduhelm as 'rife with irregularities'". The Hill. Archived from the original on 4 January 2023. Retrieved 4 January 2023.
Jen Christensen (29 December 2022). "House investigation says FDA approval process of Alzheimer's drug was 'rife with irregularities'". CNN. Archived from the original on 31 January 2024. Retrieved 31 January 2024.
Cunningham PW (16 June 2021). "The Health 202: The pricey new Alzheimer's drug adds to the pressure for drug price controls". Archived from the original on 19 November 2021. Retrieved 1 September 2021.
"Biogen CEO: committed to gathering new data on FDA-approved Alzheimer's drug". 7 June 2021. Archived from the original on 7 June 2021. Retrieved 7 June 2021.
"FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries". Kaiser Family Foundation (KFF). 10 June 2021. Archived from the original on 1 September 2021. Retrieved 1 September 2021.
"Aduhelm may not cure Alzheimer's, but it might help fix drug prices". The Economist. 15 July 2021. ISSN 0013-0613. Archived from the original on 1 September 2021. Retrieved 20 July 2021.
"How do drug tiers work?". Blue Cross Blue Shield of Michigan. Archived from the original on 15 June 2021. Retrieved 14 June 2021.
"What Medicare Part D drug plans cover". US Centers for Medicare & Medicaid Services. Archived from the original on 19 November 2021. Retrieved 14 June 2021.
"Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually". NPR. Associated Press. 10 June 2021. Archived from the original on 10 June 2021. Retrieved 11 June 2021.
"National Coverage Analysis (NCA) Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N)". Centers for Medicare & Medicaid Services (CMS). 27 September 2013. Archived from the original on 28 June 2021. Retrieved 28 June 2021.
Foley KE, Lim D, Roubein R (15 June 2021). "New Alzheimer's drug could be 'devastating' for Medicare". Politico. Archived from the original on 27 June 2021. Retrieved 19 June 2021.
Poslusny C (31 July 2018). "How much should your PET scan cost?". New Choice Health Blog. Archived from the original on 24 June 2021. Retrieved 19 June 2021.
"Medicare's Coverage Decision for the New Alzheimer's Drug and Why It Matters". KFF. 14 January 2022. Archived from the original on 20 July 2022. Retrieved 20 July 2022.
Khandekar A (20 December 2021). "Biogen halves price of Alzheimer's drug to $28,200". Reuters. Archived from the original on 20 December 2021. Retrieved 20 July 2022.
Feuerstein A, Garde D (22 September 2021). "Biogen's Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures". Stat. Archived from the original on 17 December 2021. Retrieved 11 December 2021.
Higgins-Dunn N (22 September 2021). "Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm". Fierce Pharma. Archived from the original on 11 December 2021. Retrieved 11 December 2021.

worldcat.org

search.worldcat.org

Belluck P (22 November 2021). "Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug". The New York Times. ISSN 0362-4331. Archived from the original on 20 July 2022. Retrieved 20 July 2022.
"Aduhelm may not cure Alzheimer's, but it might help fix drug prices". The Economist. 15 July 2021. ISSN 0013-0613. Archived from the original on 1 September 2021. Retrieved 20 July 2021.

xconomy.com

Zacks R (20 November 2007). "Biogen Inks $380 Million Deal with Swiss Company". Xconomy. Archived from the original on 30 October 2019. Retrieved 18 August 2015.